이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Immuneering 관리

관리 기준 확인 3/4

Immuneering's CEO는 Ben Zeskind, Feb2008 에 임명되었습니다 의 임기는 16.33 년입니다. 총 연간 보상은 $ 1.92M, 30.9% 로 구성됩니다. 30.9% 급여 및 69.1% 보너스(회사 주식 및 옵션 포함). 는 $ 4.70M 가치에 해당하는 회사 주식의 10.71% 직접 소유합니다. 4.70M. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 3.3 년입니다.

주요 정보

Ben Zeskind

최고 경영자

US$1.9m

총 보상

CEO 급여 비율	30.9%
CEO 임기	16.7yrs
CEO 소유권	10.7%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	3.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Ben Zeskind 의 보수는 Immuneering 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$56m
Mar 31 2024	n/a	n/a	-US$54m
Dec 31 2023	US$2m	US$593k	-US$53m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$2m	US$570k	-US$51m
Sep 30 2022	n/a	n/a	-US$48m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$40m
Dec 31 2021	US$2m	US$400k	-US$34m
Sep 30 2021	n/a	n/a	-US$29m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$20m
Dec 31 2020	US$806k	US$293k	-US$17m

보상 대 시장: Ben 의 총 보상 ($USD 1.92M )은 US 시장( $USD 683.56K ).

보상과 수익: Ben 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ben Zeskind (41 yo)

16.7yrs

테뉴어

US$1,918,201

보상

Dr. Benjamin J. Zeskind, also known as Ben, Ph D., MBA serves as the Co-Founder, President, Chief Executive Officer and Director of Immuneering Corporation since February 2008 and served as its Secretary....

리더십 팀

이름	위치	테뉴어	보상	소유권
Benjamin Zeskind	Co-Founder	16.7yrs	US$1.92m	10.71% $ 7.5m
Robert Carpenter	Co-Founder & Chair Emeritus	16.8yrs	US$202.74k	3.87% $ 2.7m
Brett Hall	Chief Scientific Officer	4.9yrs	US$1.40m	1.17% $ 819.8k
Harold Brakewood	Chief Business Officer	1.6yrs	US$1.57m	0.013% $ 9.2k
Mallory Morales	Principal Financial & Accounting Officer	2.2yrs	데이터 없음	0.043% $ 30.2k
Paula George	Director of Accounting & Operations and Assistant Corporate Controller	3.1yrs	데이터 없음	데이터 없음
Michael Bookman	Chief Legal Officer & Secretary	3.3yrs	데이터 없음	0.013% $ 9.1k
Leah Neufeld	Chief People Officer	2yrs	데이터 없음	0.034% $ 23.8k
Peter King	Head of Discovery & VP	no data	데이터 없음	데이터 없음
Praveen Nair	Head of Translational Pharmacology & VP	2.6yrs	데이터 없음	데이터 없음
Stephen Sebastian	Executive Director & Corporate Controller	3.1yrs	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: IMRX 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Benjamin Zeskind	Co-Founder	16.7yrs	US$1.92m	10.71% $ 7.5m
Robert Carpenter	Co-Founder & Chair Emeritus	15.4yrs	US$202.74k	3.87% $ 2.7m
Laurie Keating	Independent Director	3.6yrs	US$179.88k	0.047% $ 33.2k
Douglas Lauffenburger	Co-Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Peter Feinberg	Director	3.8yrs	US$165.67k	3.7% $ 2.6m
Ann Berman	Independent Chair	3.3yrs	US$181.38k	0.23% $ 159.9k
Diana Hausman	Independent Director	2.8yrs	US$175.38k	0% $ 0
Max Artyomov	Co-Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Bijan Nejadnik	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Tanios Bekaii-Saab	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Daniel Ahn	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Denis Guttridge	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

3.7yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: IMRX 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.

Immuneering 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Independent Chair recently bought US$123k worth of stock

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Recent updates

Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations

Independent Chair recently bought US$123k worth of stock

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Price target decreased by 12% to US$16.86

Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Share price stability

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Revenue and earnings growth

Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022)

New minor risk - Share price stability

Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022)

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

New major risk - Revenue and earnings growth

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022)

Price target decreased by 12% to US$18.71

Consensus revenue estimates decrease by 80%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$21.33

Immuneering Corporation Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering wins FDA nod to study lead asset in solid tumors

Immuneering Corporation Announces Committee Changes

Consensus forecasts updated

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2A Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immuneering Corporation Announces Management Changes

Immuneering initiated a Buy by Chardan, PT set to $18

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2500 Value Index

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

Immuneering Corporation, Annual General Meeting, Jun 21, 2022

Consensus revenue estimates fall by 75%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Immuneering Corporation Reports Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model

Immuneering Corporation (NasdaqGM:IMRX) acquired BioArkive, Inc. from Brett Hall, Praveen Nair, Daniel Flynn, Thomas Barr, Anna Travesa and Dennis Garland for $8.5 million.

Third quarter 2021 earnings released: US$0.47 loss per share

Director recently bought US$116k worth of stock

Director recently bought US$131k worth of stock

Less than half of directors are independent

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령